CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer

Mené dans 19 pays sur 719 patients atteints d'un cancer du poumon non à petites cellules, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité de l'ajout d'un traitement combinant nivolumab et ipilimumab à deux cycles d'une chimiothérapie de première ligne

Résumé en anglais

The use of immune-checkpoint inhibitors targeting the CTLA-4, PD-1, or PD-L1 signallingaxis in the modulation of anti-tumour T-cell activity has revolutionised the treatmentof lung cancer in different settings. In patients with PD-L1 expression of at least 50%, pembrolizumab (anti PD-1) andatezolizumab (anti PD-L1) have been approved by the US Food and Drug Administrationas first-line single-agent treatments because they significantly prolong overall survivalcompared with platinum-based chemotherapy, in patients with both squamous and non-squamoustumours without sensitising EGFR mutations or ALK rearrangements;